Gemcitabine-cisplatin versus gemcitabine-oxaliplatin doublet chemotherapy in advanced gallbladder cancers: a match pair analysis

Background Gemcitabine-cisplatin (GC) and gemcitabine-oxaliplatin (GO) are the most commonly used regimens in advanced gallbladder cancer (GBC). Methods The data of patients with advanced GBC, treated between January 2013 and June 2015 were retrieved. A 1:1 matching without replacement was performed by using nearest neighbour matching method. Results 326 patients (163 GC and 163 GO), were matched 1:1 by age and gender. The response rates for GC and GO were 31.2% and 36.3% (p=0.350). The overall median EFS was 4.34 months (95% CI 4.030 - 4.644 months). The median EFS was 4.67 months (95% CI: 4.060 - 5.271 months) in GC cohort and 3.88 months (95% CI: 3.369 - 4.385 months) in GO cohort (p=0.023). The overall median OS was 8.016 months (95% CI 7.361 - 8.672 months). The median OS was 8.02 months (95% CI: 7.257 - 8.776 months) in GC cohort and 7.79 months (95% CI: 6.690 - 8.88 months) in GO cohort (p=0.455). The incidence of Grade 2/3 peripheral neuropathy (9.2% vs. 3.1%; p=0.445) and Grade 3/4 transamintis (14.7% vs. 6.1%) was higher with GO while the incidence of anemia (22.1% vs. 6.7%; p